Life sciences and health care M&A update: Q4 2025

US health care M&A deal value declined to $46 billion in 2025 from $62 billion in 2024, yet Q4 2025 rebounded sharply as buyers sought scale and innovation.

Life sciences and health care trends

  • Health care services
    Hospital acquisitions of physician practices were associated with 3.3% higher hospital service prices and 15.1% higher physician prices, while integrated physicians prices rose 9% after additional specialty acquisitions.1
  • Health care technology
    Venture deployment reached $2.0 billion in Q4, and $11.3 billion across 323 rounds in 2025, signaling continued activity but more selective underwriting.2
  • Life sciences and pharma services
    Q4 2025 saw a clear resurgence in life sciences and biopharma dealmaking, with multiple multibillion‑dollar transactions driving overall momentum and pushing total M&A value sharply higher quarter over quarter.3
  • Medical devices and supplies
    The medical products and devices (MedTech) sector is being propelled by rising global health care spending, aging populations, and accelerating demand for technology-driven innovation, while continued robust M&A activity underscores confidence in durable growth fundamentals.4
  • Payors and payor services
    In Medicare Advantage, enrollment continued to grow (now a majority of eligible beneficiaries) but at a slower pace, with Special Needs Plans (SNPs) driving a disproportionate share of growth.5

 

This newsletter is a periodic compilation of certain capital markets information. Information contained in this newsletter should not be construed as a recommendation to sell or a recommendation to buy any security. Any reference to or omission of any reference to any company in this newsletter shall not be construed as a recommendation to sell, buy, or take any other action with respect to any security of any such company. We are not soliciting any action with respect to any security or company based on this newsletter. This newsletter is published solely for the general information of clients and friends of Deloitte Corporate Finance LLC. It does not take into account the particular investment objectives, financial situation, or needs of individual recipients. Certain transactions, including those involving early-stage companies, give rise to substantial risk and are not suitable for all investors. This newsletter is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon as such. Prediction of future events is inherently subject to both known risks, uncertainties, and other factors that may cause actual results to vary materially. We are under no obligation to update the information contained in this newsletter. We and our affiliates and related entities, partners, principals, directors, and employees, including persons involved in the preparation or issuance of this newsletter, may from time to time have “long” and “short” positions in, and buy or sell, the securities, or derivatives (including options) thereof, of companies mentioned herein. The companies mentioned in this newsletter may be: (i) investment banking clients of Deloitte Corporate Finance LLC; or (ii) clients of Deloitte Financial Advisory Services LLP and its related entities. The decision to include any company for mention or discussion in this newsletter is wholly unrelated to any audit or other services that Deloitte Corporate Finance LLC may provide or to any audit services or any services that any of its affiliates or related entities may provide to such company. No part of this newsletter may be copied or duplicated in any form by any means, or redistributed without the prior written consent of Deloitte Corporate Finance LLC.

References

1 PCE Investment Bankers, “Healthcare Q4 2025,” January 14, 2026.
2 JPMorgan, “Biopharma and medtech activity in Q4 2025,” January 7, 2026
3 Wilson Sonsini, The life sciences report, January 2026.
4 Harris Williams, Medical Products & Devices Q4 2025 report, December 5, 2025.
5 Centers for Medicare & Medicaid Services, “Medicare Advantage and Medicare prescription drug programs expected to remain stable in 2026,” press release, September 26, 2025.

Did you find this useful?

Thanks for your feedback